Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Comprehensive Insider Report for ATE

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on Jul 21, 2022 6:26pm

43 Views

Post# 34841809

RE:RE:RE:RE:RE:Comprehensive Insider Report for ATE

hiw does someone dumb as you come up with so good comebacks? You won this time with this mic drop

Inthepez wrote:

Twice as obstinate, quarter as entertaining as dumpster LOL!

StockingUp21 wrote:

Lol twice as mad and a quarter as smart as mugoo.

Inthepez wrote: Why don't you do it for us. Bet you can't. LOL!